CD19 and leukemia: To assess the impact of GSK priming on CAR T-cell antitumor efficacy, we treated NCG mice bearing the Nalm6-lucif-EGFP leukemia with a low dose (2 × 105) of GSK-primed or control CD19-CAR T cells, or mock T cells without CAR transduction.